Research programme: anticancer therapuetics - Satya Pharma
Alternative Names: Oncogene targeting small molecule therapeutics - Satya PharmaLatest Information Update: 28 Aug 2026
At a glance
- Originator Satya Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Oncogene modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for research development in Cancer in India
- 19 Jul 2022 Early research in Cancer in India (unspecified route) before July 2022 (Satya Pharma pipeline, July 2022 )